Cargando…

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model

Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaumaya, Pravin T. P., Guo, Linlin, Overholser, Jay, Penichet, Manuel L., Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/
https://www.ncbi.nlm.nih.gov/pubmed/33117602
http://dx.doi.org/10.1080/2162402X.2020.1818437
_version_ 1783593622951690240
author Kaumaya, Pravin T. P.
Guo, Linlin
Overholser, Jay
Penichet, Manuel L.
Bekaii-Saab, Tanios
author_facet Kaumaya, Pravin T. P.
Guo, Linlin
Overholser, Jay
Penichet, Manuel L.
Bekaii-Saab, Tanios
author_sort Kaumaya, Pravin T. P.
collection PubMed
description Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depends on a combinatorial approach. Contrary to mAbs chimeric B-cell cancer vaccines incorporating a “promiscuous” T-cell epitope have the advantage of producing a polyclonal B-cell antibody that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. Here, we describe a novel PD-1 B-cell peptide epitope vaccine (amino acid 92–110; PD1-Vaxx) linked to a measles virus fusion peptide (MVF) amino acid 288–302 via a four amino acid residue (GPSL) emulsified in Montanide ISA 720VG that aims to induce the production of polyclonal antibodies that block PD-1 signaling and thus trigger anticancer effects similar to nivolumab. In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. Furthermore, the combination of PD1-Vaxx with combo HER-2 peptide vaccine (B-Vaxx) showed enhanced inhibition of tumor growth in colon carcinoma BALB/c model challenged with CT26/HER-2 cells. The PD-1 or combined vaccines were safe with no evidence of toxicity or autoimmunity.
format Online
Article
Text
id pubmed-7553530
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75535302020-10-27 Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model Kaumaya, Pravin T. P. Guo, Linlin Overholser, Jay Penichet, Manuel L. Bekaii-Saab, Tanios Oncoimmunology Original Research Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depends on a combinatorial approach. Contrary to mAbs chimeric B-cell cancer vaccines incorporating a “promiscuous” T-cell epitope have the advantage of producing a polyclonal B-cell antibody that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. Here, we describe a novel PD-1 B-cell peptide epitope vaccine (amino acid 92–110; PD1-Vaxx) linked to a measles virus fusion peptide (MVF) amino acid 288–302 via a four amino acid residue (GPSL) emulsified in Montanide ISA 720VG that aims to induce the production of polyclonal antibodies that block PD-1 signaling and thus trigger anticancer effects similar to nivolumab. In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. Furthermore, the combination of PD1-Vaxx with combo HER-2 peptide vaccine (B-Vaxx) showed enhanced inhibition of tumor growth in colon carcinoma BALB/c model challenged with CT26/HER-2 cells. The PD-1 or combined vaccines were safe with no evidence of toxicity or autoimmunity. Taylor & Francis 2020-10-01 /pmc/articles/PMC7553530/ /pubmed/33117602 http://dx.doi.org/10.1080/2162402X.2020.1818437 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Kaumaya, Pravin T. P.
Guo, Linlin
Overholser, Jay
Penichet, Manuel L.
Bekaii-Saab, Tanios
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title_full Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title_fullStr Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title_full_unstemmed Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title_short Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
title_sort immunogenicity and antitumor efficacy of a novel human pd-1 b-cell vaccine (pd1-vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like her-2 b-cell epitope vaccines (b-vaxx) in a syngeneic mouse model
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/
https://www.ncbi.nlm.nih.gov/pubmed/33117602
http://dx.doi.org/10.1080/2162402X.2020.1818437
work_keys_str_mv AT kaumayapravintp immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel
AT guolinlin immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel
AT overholserjay immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel
AT penichetmanuell immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel
AT bekaiisaabtanios immunogenicityandantitumorefficacyofanovelhumanpd1bcellvaccinepd1vaxxandcombinationimmunotherapywithdualtrastuzumabpertuzumablikeher2bcellepitopevaccinesbvaxxinasyngeneicmousemodel